Evidence map›Paper›PMID 39389669›Full record

ArticleMethods in enzymology2024

AP endonuclease 1: Biological updates and advances in activity analysis.

Karen H Almeida, Morgan E Andrews, Robert W Sobol

Abstract read
In one paragraph

Article in Methods in enzymology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Karen H AlmeidaPhysical Sciences Department, Rhode Island College, Providence, RI, United States.
Morgan E AndrewsDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School & Legorreta Cancer Center, Brown University, Providence, RI, United States.
Robert W SobolDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School & Legorreta Cancer Center, Brown University, Providence, RI, United States. Electronic address: rwsobol@brown.edu.

Funding

A Systems Approach to Mapping the DNA Damage ResponseR01ES014811 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2005 to 2021
$8.6M
Research Project 3P01ES028949 · NIEHS · FLORIDA GULF COAST UNIVERSITY · PI PARSONS, MICHAEL · 2018 to 2024
$3.8M
Investigating genetic ancestry influences on oral cavity and laryngeal cancer survival disparitiesR01CA238061 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI RAGIN, CAMILLE C., SOBOL, ROBERT W · 2019 to 2023
$3.4M
Measuring genomic DNA damage and DNA repair capacity in longitudinal population samples - a step towards precision preventionU01ES029518 · NIEHS · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2018 to 2022
$2.7M
Barcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variabilityR44ES032522 · NIEHS · AMELIA TECHNOLOGIES, LLC · PI GEORGE, JAY, SOBOL, ROBERT W · 2021 to 2023
$1.9M
The Paternal Age Effect - Enhanced Germ Cell Mutagenesis Modulated by the TRP53/APE1/MDM2 Tumor Suppressor AxisR01AG069740 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KRAIG, ELLEN · 2020 to 2024
$1.8M
SON-mediated RNA splicing in glioblastomaR01CA236911 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHN, ERIN EUN-YOUNG · 2020 to 2024
$1.8M
NCI NIH HHS R01 CA236911NCI NIH HHS R01 CA238061NIA NIH HHS R01 AG069740NIEHS NIH HHS P01 ES028949NIEHS NIH HHS R01 ES014811NIEHS NIH HHS R44 ES032522NIEHS NIH HHS U01 ES029518
6 · The paper itself

Abstract

Apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1, APEX1, REF1, HAP1) is an abasic site-specific endonuclease holding critical roles in numerous biological functions including base excision repair, the DNA damage response, redox regulation of transcription factors, RNA processing, and gene regulation. Pathologically, APE1 expression and function is linked with numerous human diseases including cancer, highlighting the importance of sensitive and quantitative assays to measure APE1 activity. Here, we summarize biochemical and biological roles for APE1 and expand on the discovery of APE1 inhibitors. Finally, we highlight the development of assays to monitor APE1 activity, detailing a recently improved and stabilized DNA Repair Molecular Beacon assay to analyze APE1 activity. The assay is amenable to analysis of purified protein, to measure changes in APE1 activity in cell lysates, to monitor human patient samples for defects in APE1 function, or the cellular and biochemical response to APE1 inhibitors.

Indexed as

DNA-(Apurinic or Apyrimidinic Site) LyaseDNA RepairEnzyme AssaysEnzyme InhibitorsDNA DamageHumansAPEX1 protein, humanDNA-(Apurinic or Apyrimidinic Site) LyaseEnzyme InhibitorsAPE1APEX1Apurinic/apyrimidinic endodeoxyribonuclease 1Base excision repairDNA repairMolecular beacon

Identifiers

PMID39389669
PMCPMC12553405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.